Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.

Recommendations for classification in AML have been published by the European Leukemia Network (ELN). We evaluated these recommendations within an independent cohort of 954 adult de novo AML patients. No differences in outcome for subgroups intermediate I versus II were found. Therefore we renewed the reporting system and defined the subgroups as follows: favorable (CBF leukemias, or intermediate cytogenetics with NPM1mutation (mut) or biallelic CEBPAmut), intermediate I (intermediate cytogenetics), intermediate II (intermediate cytogenetics and at least one of the following: MLL-PTD, RUNX1mut, FLT3-ITD/wt ratio ≥ 0.5), and adverse (adverse cytogenetics). Significant differences in outcomes between all four subgroups were found.